Related Experiment Videos
ERBB2 in pediatric cancer: innocent until proven guilty
1Department of Developmental Neurobiology, St. Jude Children's Research Hospital, 332 N. Lauderdale Street, Memphis, Tennessee 38105, USA. Richard.Gilbertson@stjude.org
The Oncologist
|August 5, 2005
Summary
Pediatric oncologists can adapt adult cancer therapies by verifying molecular targets, like the ERBB2 oncogene, are also relevant in childhood cancers. This ensures safe and effective introduction of targeted treatments for pediatric patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Adult oncology has made significant strides with molecularly targeted chemotherapies.
- Translating these successes to pediatric oncology requires careful validation.
Purpose of the Study:
- To review the criteria for identifying molecular targets in pediatric cancers.
- To assess the potential of adult-targeted therapies for childhood cancers, using ERBB2 as a case study.
Main Methods:
- Literature review focusing on molecular targets in adult and pediatric cancers.
- Analysis of the ERBB2 oncogene as a model for target validation.
Main Results:
- Molecular targets effective in adult cancers may not be directly applicable to pediatric cancers.
- The ERBB2 oncogene serves as an example for evaluating target relevance in childhood malignancies.
Conclusions:
- Rigorous validation of molecular targets is crucial before introducing adult therapies into pediatric oncology.
- Understanding specific pediatric cancer biology is essential for successful targeted therapy development.